Lipocine Inc. 8-K

What Happened
Lipocine Inc. announced on June 3, 2026 that shareholders approved the Sixth Amended and Restated 2014 Stock and Incentive Plan, increasing individual award limits and the number of shares available for awards. The Board adopted the Sixth Amendment on April 10, 2026; shareholder approval was obtained at the June 3, 2026 annual meeting. At the same meeting the company’s four director nominees were elected and Tanner LLC was ratified as the independent registered public accounting firm for fiscal 2026.

Key Details

• Stock plan changes approved: individual award limit raised from 25,000 to 100,000 shares; authorized shares for awards increased by 400,000 to a total of up to 1,000,000 shares (subject to adjustment).
• Board action and approval dates: Sixth Amendment adopted April 10, 2026; shareholder approval June 3, 2026.
• Director election vote totals:
  • Dr. Mahesh V. Patel — For: 1,612,440; Withheld: 248,800; Broker non-vote: 2,916,331
  • John W. Higuchi — For: 1,664,789; Withheld: 196,451; Broker non-vote: 2,916,331
  • Dr. Jill M. Jene — For: 1,627,721; Withheld: 233,519; Broker non-vote: 2,916,331
  • Dr. Richard Dana Ono — For: 1,660,659; Withheld: 200,581; Broker non-vote: 2,916,331
• Auditor ratification: Tanner LLC ratified for FY2026 (For: 4,538,146; Against: 178,276; Abstain: 61,149).
• Advisory (say-on-pay) vote on executive compensation passed (For: 1,626,360; Against: 208,110; Abstain: 26,770; Broker non-vote: 2,916,331).

Why It Matters
The approved amendment increases the pool and per-person limits for stock-based awards, giving Lipocine more flexibility to grant options, RSUs or other equity incentives to employees, directors and consultants. That can help recruit and retain talent but may lead to potential dilution if awards are issued and exercised. Re-election of the incumbent directors and ratification of Tanner LLC provide continuity in governance and auditing for investors.